May 18, 2026 06:01 AM EDTUpdated 10:50 AM
PharmaFDA+
AstraZeneca's blood pressure pill approved, but competition could be around the corner
Elizabeth Cairns
Senior biopharma journalist
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
May 18, 2026 06:01 AM EDTUpdated 10:50 AM
PharmaFDA+
AstraZeneca's blood pressure pill approved, but competition could be around the corner
Elizabeth Cairns
Senior biopharma journalist

AstraZeneca picks up FDA approval for hypertension drug

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

FDA approves AstraZeneca’s new kind of hypertension drug

Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm